A $46M Bet on a New Way to Treat the Most Common Genetic Kidney Disease

Jan de Vries · 2026-08-07

### A Big Win for a Small Scottish Biotech You might not have heard of Mironid, but this Glasgow-based biotech just landed a seriously impressive vote of confidence. The company has closed a $46 million Series B financing round to push its lead drug candidate through clinical development. That candidate targets Autosomal Dominant Polycystic Kidney Disease, or ADPKD, the most common inherited kidney disorder out there. The round was led by the Scottish National Investment Bank, with backing from a syndicate that includes Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that kind of lineup, it's clear this isn't just another funding round—it's a signal that something meaningful is happening in rare disease research. ### Why This Matters for Millions of Patients Here's the sobering reality: ADPKD affects over 12 million people worldwide. Half of those patients will develop kidney failure by age 60. That's a staggering number, and current treatment options are limited. Neil Wilkie, Mironid's CEO, put it plainly: securing this funding from such a high-calibre group validates the company's approach to tackling kidney diseases like ADPKD. "This financing will allow us to progress the clinical development of our lead candidate," Wilkie said, "bringing us closer to transforming the treatment landscape for patients with rare kidney diseases." ### The Science Behind the Hope Mironid spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. The company's focus is on developing drug candidates for degenerative and rare genetic kidney diseases, plus major inflammatory diseases and cancer. The lead candidate is what they call a LoAc small molecule. It's designed to directly target cyclic AMP, or cAMP, a cellular signal that's active at every stage of ADPKD—from initiation all the way to end-stage disease. cAMP drives both cell proliferation and fluid secretion within the cysts, which is what causes the kidneys to fail. What's really encouraging is the preclinical data. The company reports significant efficacy and a favorable safety profile across disease endpoints, including reductions in cyst number and kidney volume. The idea is that by preventing new cyst formation and stopping existing ones from growing, this approach could offer a more durable treatment with a better side-effect profile than what's currently available. ### What's Next for Mironid The fresh capital follows an earlier Series A extension round, bringing Mironid's total funding since inception to roughly $47.7 million. The money will go toward advancing the clinical development of the LoAc candidate for ADPKD patients. Beyond ADPKD, the pipeline targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways implicated in disease progression. The company operates on a research-and-development-led model, funded through venture capital and strategic investment, with the long-term goal of moving programs through preclinical and clinical trials toward commercialization. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up nicely: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." ### Why This Funding Round Matters This isn't just another biotech funding announcement. It's a testament to what happens when world-class research meets patient-driven purpose. For the millions living with ADPKD, this could mean a future with better options, fewer side effects, and more time before kidney failure becomes a reality. We'll be watching closely as Mironid moves its candidate through the clinic. If the preclinical promise holds up, this could be a game-changer for rare kidney disease treatment. And for a company that started as a university spinout, that's a remarkable journey worth following.